New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
07:35 EDTADXSAdvaxis receives notice of allowance for 2 patent applications
Advaxis has received notice of allowance from the U.S. Patent and Trademark Office on two patents covering the composition and methods of use for ADXS-cHER2. Advaxis is developing ADXS-cHER2 to target the Her2 receptor, which is overexpressed in certain solid-tumor cancers, including bone cancer, breast cancer, esophageal, and gastric cancer. Advaxis plans to initiate a Phase 1 trial with ADXS-cHER2 in pediatric osteosarcoma, for which it received Orphan Drug Designation, and is pursuing early development clinical collaborations for breast, esophageal and gastric cancers.
News For ADXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
11:06 EDTADXSAduro Biotech selloff an overreaction to adverse event, says Roth Capital
Subscribe for More Information
November 17, 2015
09:18 EDTADXSAdvaxis to receive $1.6M through NJ NOL Program
Advaxis announced the company has received preliminary approval for a $1.8M tax credit from the New Jersey Technology Business Tax Certificate Transfer, or NOL, Program for the year 2015. The company anticipates it will be able to transfer this credit and receive approximately $1.6M in cash in December.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use